Skip to main content
. Author manuscript; available in PMC: 2021 Apr 21.
Published in final edited form as: Endocr Pract. 2018 Aug 7;24(8):710–717. doi: 10.4158/EP-2018-0022

Fig. 2.

Fig. 2.

Kaplan-Meier analysis for disease progression according to 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) level doubling time (DT) in the entire cohort (n = 49, A) and only patients with small-intestine neuroendocrine tumors (NETs), or with NET of unknown primary location (n = 19, B), and only patients with pancreatic NETs (n = 23, C).